Insider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 187 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 187 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $481.63, for a total transaction of $90,064.81. Following the transaction, the director owned 5,286 shares of the company’s stock, valued at approximately $2,545,896.18. This represents a 3.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Trading Up 1.8%

United Therapeutics stock traded up $8.36 during mid-day trading on Wednesday, reaching $484.72. The company had a trading volume of 328,119 shares, compared to its average volume of 579,435. The business has a fifty day simple moving average of $455.16 and a 200 day simple moving average of $371.12. The company has a market cap of $20.87 billion, a P/E ratio of 18.37, a P/E/G ratio of 4.76 and a beta of 0.86. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $492.62.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the company earned $6.39 EPS. Research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of several research reports. UBS Group boosted their price target on United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Wells Fargo & Company raised their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “buy (b-)” rating on shares of United Therapeutics in a report on Monday. Finally, Oppenheimer increased their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Chung Wu Investment Group LLC acquired a new stake in United Therapeutics during the 2nd quarter worth about $29,000. WealthCollab LLC grew its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. SVB Wealth LLC acquired a new position in United Therapeutics in the first quarter valued at approximately $32,000. Finally, Wilmington Savings Fund Society FSB boosted its holdings in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.